Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma

Douglas R. Adkins, Donna Salzman, David Boldt, John Kuhn, Rebecca Irvin, G. David Roodman, Roger Lyons, Lon Smith, Cesar O. Freytes, C. Frederick LeMaistre

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Purpose: We investigated the feasibility of escalating doses of dacarbazine (DTIC) in combination with high-dose cyclophosphamide, carmustine, and etoposide (CBV) given with autologous stem-cell transplantation in 33 patients with relapsed or refractory lymphoma or multiple myeloma. Patients and Methods: Eligible patients were treated in this phase I study with cyclophosphamide (7.2 g/m2), carmustine (BCNU) (600 mg/m2), etoposide (2.4 g/m2), and escalating doses of DTIC (3,000 to 6,591 mg/m2) administered either as a 2- (in 23 patients) or a 6- (in 10 patients) hour infusion to determine the maximum-tolerated dose (MTD) of DTIC and the toxicity profile of this combination. Results: The MTD of DTIC infused over 2 hours and given with the CBV regimen was 3,900 mg/m2, with the dose- limiting toxicity being hypotension. Seven patients experienced transient acute hypocalcemia in association with the DTIC infusion. Prolonging the DTIC infusion to 6 hours or administration of supplemental calcium did not allow further dose escalation of DTIC to occur. Other nonhematologic toxicities observed with this regimen have been reported with CBV alone. Of 25 patients assessable for tumor response at first evaluation posttransplant, 13 (52%) were in complete remission (CR), four (16%) were in partial remission (PR), five (20%) had stable disease (SD), and three (12%) had progressive disease (PROG). Of 31 patients assessable for relapse-free survival, 22 are alive with 13 in CR, one in PR, two with SD, and six with PROG at a median follow- up duration of 313 days (range, 35 to 749+). Treatment-related mortality occurred in six patients (18%). Conclusion: The feasibility of combining DTIC in high doses with the CBV regimen has been demonstrated. Dose-limiting hypotension is transient and reversible when DTIC is administered at 3,900 mg/m2 with CBV. Future trials to evaluate the effect of the addition of DTIC to the CBV regimen on response rate and relapse-free survival are encouraged.

Original languageEnglish (US)
Pages (from-to)1890-1901
Number of pages12
JournalJournal of Clinical Oncology
Volume12
Issue number9
StatePublished - Sep 1994
Externally publishedYes

Fingerprint

Carmustine
Dacarbazine
Stem Cell Transplantation
Etoposide
Multiple Myeloma
Cyclophosphamide
Lymphoma
Maximum Tolerated Dose
Hypotension
Recurrence
Survival
Hypocalcemia

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Adkins, D. R., Salzman, D., Boldt, D., Kuhn, J., Irvin, R., Roodman, G. D., ... LeMaistre, C. F. (1994). Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma. Journal of Clinical Oncology, 12(9), 1890-1901.

Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma. / Adkins, Douglas R.; Salzman, Donna; Boldt, David; Kuhn, John; Irvin, Rebecca; Roodman, G. David; Lyons, Roger; Smith, Lon; Freytes, Cesar O.; LeMaistre, C. Frederick.

In: Journal of Clinical Oncology, Vol. 12, No. 9, 09.1994, p. 1890-1901.

Research output: Contribution to journalArticle

Adkins, DR, Salzman, D, Boldt, D, Kuhn, J, Irvin, R, Roodman, GD, Lyons, R, Smith, L, Freytes, CO & LeMaistre, CF 1994, 'Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma', Journal of Clinical Oncology, vol. 12, no. 9, pp. 1890-1901.
Adkins, Douglas R. ; Salzman, Donna ; Boldt, David ; Kuhn, John ; Irvin, Rebecca ; Roodman, G. David ; Lyons, Roger ; Smith, Lon ; Freytes, Cesar O. ; LeMaistre, C. Frederick. / Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma. In: Journal of Clinical Oncology. 1994 ; Vol. 12, No. 9. pp. 1890-1901.
@article{de3f268456de41e5bb08b200ae25fc11,
title = "Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma",
abstract = "Purpose: We investigated the feasibility of escalating doses of dacarbazine (DTIC) in combination with high-dose cyclophosphamide, carmustine, and etoposide (CBV) given with autologous stem-cell transplantation in 33 patients with relapsed or refractory lymphoma or multiple myeloma. Patients and Methods: Eligible patients were treated in this phase I study with cyclophosphamide (7.2 g/m2), carmustine (BCNU) (600 mg/m2), etoposide (2.4 g/m2), and escalating doses of DTIC (3,000 to 6,591 mg/m2) administered either as a 2- (in 23 patients) or a 6- (in 10 patients) hour infusion to determine the maximum-tolerated dose (MTD) of DTIC and the toxicity profile of this combination. Results: The MTD of DTIC infused over 2 hours and given with the CBV regimen was 3,900 mg/m2, with the dose- limiting toxicity being hypotension. Seven patients experienced transient acute hypocalcemia in association with the DTIC infusion. Prolonging the DTIC infusion to 6 hours or administration of supplemental calcium did not allow further dose escalation of DTIC to occur. Other nonhematologic toxicities observed with this regimen have been reported with CBV alone. Of 25 patients assessable for tumor response at first evaluation posttransplant, 13 (52{\%}) were in complete remission (CR), four (16{\%}) were in partial remission (PR), five (20{\%}) had stable disease (SD), and three (12{\%}) had progressive disease (PROG). Of 31 patients assessable for relapse-free survival, 22 are alive with 13 in CR, one in PR, two with SD, and six with PROG at a median follow- up duration of 313 days (range, 35 to 749+). Treatment-related mortality occurred in six patients (18{\%}). Conclusion: The feasibility of combining DTIC in high doses with the CBV regimen has been demonstrated. Dose-limiting hypotension is transient and reversible when DTIC is administered at 3,900 mg/m2 with CBV. Future trials to evaluate the effect of the addition of DTIC to the CBV regimen on response rate and relapse-free survival are encouraged.",
author = "Adkins, {Douglas R.} and Donna Salzman and David Boldt and John Kuhn and Rebecca Irvin and Roodman, {G. David} and Roger Lyons and Lon Smith and Freytes, {Cesar O.} and LeMaistre, {C. Frederick}",
year = "1994",
month = "9",
language = "English (US)",
volume = "12",
pages = "1890--1901",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "9",

}

TY - JOUR

T1 - Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma

AU - Adkins, Douglas R.

AU - Salzman, Donna

AU - Boldt, David

AU - Kuhn, John

AU - Irvin, Rebecca

AU - Roodman, G. David

AU - Lyons, Roger

AU - Smith, Lon

AU - Freytes, Cesar O.

AU - LeMaistre, C. Frederick

PY - 1994/9

Y1 - 1994/9

N2 - Purpose: We investigated the feasibility of escalating doses of dacarbazine (DTIC) in combination with high-dose cyclophosphamide, carmustine, and etoposide (CBV) given with autologous stem-cell transplantation in 33 patients with relapsed or refractory lymphoma or multiple myeloma. Patients and Methods: Eligible patients were treated in this phase I study with cyclophosphamide (7.2 g/m2), carmustine (BCNU) (600 mg/m2), etoposide (2.4 g/m2), and escalating doses of DTIC (3,000 to 6,591 mg/m2) administered either as a 2- (in 23 patients) or a 6- (in 10 patients) hour infusion to determine the maximum-tolerated dose (MTD) of DTIC and the toxicity profile of this combination. Results: The MTD of DTIC infused over 2 hours and given with the CBV regimen was 3,900 mg/m2, with the dose- limiting toxicity being hypotension. Seven patients experienced transient acute hypocalcemia in association with the DTIC infusion. Prolonging the DTIC infusion to 6 hours or administration of supplemental calcium did not allow further dose escalation of DTIC to occur. Other nonhematologic toxicities observed with this regimen have been reported with CBV alone. Of 25 patients assessable for tumor response at first evaluation posttransplant, 13 (52%) were in complete remission (CR), four (16%) were in partial remission (PR), five (20%) had stable disease (SD), and three (12%) had progressive disease (PROG). Of 31 patients assessable for relapse-free survival, 22 are alive with 13 in CR, one in PR, two with SD, and six with PROG at a median follow- up duration of 313 days (range, 35 to 749+). Treatment-related mortality occurred in six patients (18%). Conclusion: The feasibility of combining DTIC in high doses with the CBV regimen has been demonstrated. Dose-limiting hypotension is transient and reversible when DTIC is administered at 3,900 mg/m2 with CBV. Future trials to evaluate the effect of the addition of DTIC to the CBV regimen on response rate and relapse-free survival are encouraged.

AB - Purpose: We investigated the feasibility of escalating doses of dacarbazine (DTIC) in combination with high-dose cyclophosphamide, carmustine, and etoposide (CBV) given with autologous stem-cell transplantation in 33 patients with relapsed or refractory lymphoma or multiple myeloma. Patients and Methods: Eligible patients were treated in this phase I study with cyclophosphamide (7.2 g/m2), carmustine (BCNU) (600 mg/m2), etoposide (2.4 g/m2), and escalating doses of DTIC (3,000 to 6,591 mg/m2) administered either as a 2- (in 23 patients) or a 6- (in 10 patients) hour infusion to determine the maximum-tolerated dose (MTD) of DTIC and the toxicity profile of this combination. Results: The MTD of DTIC infused over 2 hours and given with the CBV regimen was 3,900 mg/m2, with the dose- limiting toxicity being hypotension. Seven patients experienced transient acute hypocalcemia in association with the DTIC infusion. Prolonging the DTIC infusion to 6 hours or administration of supplemental calcium did not allow further dose escalation of DTIC to occur. Other nonhematologic toxicities observed with this regimen have been reported with CBV alone. Of 25 patients assessable for tumor response at first evaluation posttransplant, 13 (52%) were in complete remission (CR), four (16%) were in partial remission (PR), five (20%) had stable disease (SD), and three (12%) had progressive disease (PROG). Of 31 patients assessable for relapse-free survival, 22 are alive with 13 in CR, one in PR, two with SD, and six with PROG at a median follow- up duration of 313 days (range, 35 to 749+). Treatment-related mortality occurred in six patients (18%). Conclusion: The feasibility of combining DTIC in high doses with the CBV regimen has been demonstrated. Dose-limiting hypotension is transient and reversible when DTIC is administered at 3,900 mg/m2 with CBV. Future trials to evaluate the effect of the addition of DTIC to the CBV regimen on response rate and relapse-free survival are encouraged.

UR - http://www.scopus.com/inward/record.url?scp=0028046850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028046850&partnerID=8YFLogxK

M3 - Article

VL - 12

SP - 1890

EP - 1901

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 9

ER -